The FDA approved ARYNTA, an oral liquid solution of lisdexamfetamine dimesylate, on June 16, 2025, making it the first-ever liquid formulation of the well-known ADHD stimulant available for children aged six and older. Developed by Azurity Pharmaceuticals, ARYNTA contains the same active ingredient found in Vyvanse but delivers it in a 10 mg/mL liquid form designed specifically for patients who struggle to swallow pills — a group that includes young children, elderly adults with dysphagia, and individuals with cognitive or neurological conditions that make capsule-based medications impractical. For families navigating an ADHD diagnosis in a young child, this approval represents a genuinely meaningful shift in how treatment can be delivered. But ARYNTA is not the only development worth tracking.
The FDA is currently reviewing two additional ADHD medications with target action dates in 2026: centanafadine, a first-in-class non-stimulant triple reuptake inhibitor from Otsuka Pharmaceutical, and CTx-1301, a novel extended-release formulation of dexmethylphenidate from Cingulate Inc. Both are seeking approval for children aged six and older, adolescents, and adults. For caregivers, clinicians, and anyone concerned with brain health across the lifespan, this is a period of unusual activity in the ADHD treatment landscape. This article walks through what ARYNTA’s approval means in practical terms, how the two pending medications differ from existing options, what the clinical trial data actually shows for young children, and what families should weigh when considering these treatments — including the limitations and risks that don’t always make it into the headlines.
Table of Contents
- What Is the New ADHD Medication Approved for Children as Young as 6?
- Why a Liquid Formulation Changes ADHD Treatment for Young Children
- Centanafadine Could Become the First Non-Stimulant Triple Reuptake Inhibitor for ADHD
- How CTx-1301 Compares to Existing Extended-Release Stimulants
- Weight Loss Warnings and What Families Should Watch For
- What This Means for Older Adults and Dementia Caregiving
- What to Expect Through the Rest of 2026
- Conclusion
- Frequently Asked Questions
What Is the New ADHD Medication Approved for Children as Young as 6?
ARYNTA is lisdexamfetamine dimesylate in oral solution form, classified as a Schedule II controlled substance. The starting dose is 30 mg taken once daily in the morning, with physicians able to adjust the dose in 10 to 20 mg increments on a weekly basis up to a maximum of 70 mg per day. The liquid should be stored at room temperature between 68°F and 77°F. For a six-year-old who gags on capsules or a grandparent with Parkinson’s-related swallowing difficulties, this formulation removes one of the most persistent practical barriers to consistent ADHD treatment. It is also approved for moderate-to-severe binge eating disorder in adults, though that indication is separate from its pediatric ADHD use. It matters to be precise about what ARYNTA is and is not. It is not a new molecule.
Lisdexamfetamine has been on the market since 2007 under the brand name Vyvanse and went generic in 2023. What is new is the delivery method. Parents who have been crushing capsules, mixing powder into applesauce, or using compounding pharmacies to get liquid versions of stimulant medications now have an FDA-approved, commercially manufactured option with standardized dosing. That distinction — between a novel drug and a novel formulation — is important because it means the safety and efficacy profile of lisdexamfetamine is already well established across nearly two decades of clinical use. Availability is one significant caveat. Azurity Pharmaceuticals has indicated that ARYNTA is expected to reach pharmacies by mid-2026. So while the FDA approval is already in hand, families cannot yet walk into a pharmacy and fill this prescription. For those currently managing a young child’s ADHD treatment, the practical impact is still months away.
Why a Liquid Formulation Changes ADHD Treatment for Young Children
Anyone who has tried to get a six-year-old to swallow a capsule understands the problem ARYNTA is designed to solve. Medication adherence in young children is notoriously difficult, and the physical act of swallowing a pill is often the first point of failure. Studies on pediatric medication compliance consistently show that liquid formulations improve adherence rates in children under ten, and ADHD is a condition where inconsistent dosing can have cascading effects on behavior, learning, and family dynamics. A child who skips doses because the pill is too hard to swallow is not getting the benefit the prescription was designed to provide. However, a liquid stimulant also introduces considerations that capsules do not. Precise measurement matters — a 10 mg/mL concentration means that even small errors in measuring can lead to meaningful dose variations, particularly at the lower end of the dosing range for a small child.
Parents and caregivers will need to use the measuring device provided with the medication, not a kitchen spoon. There is also the storage and security question: a liquid controlled substance stored at room temperature must be kept out of reach of children and other household members, and its form factor may be less obviously “medication” to a curious child than a pill bottle. If a household includes individuals with substance use disorders, the accessibility of a palatable liquid stimulant is something prescribers should discuss openly with families. The liquid form also has relevance beyond pediatrics. Elderly patients with dementia-related dysphagia, stroke survivors with swallowing impairment, and individuals with intellectual disabilities who may also have co-occurring ADHD all stand to benefit. Brain health is not siloed by age, and a formulation that works for a six-year-old may also work for an eighty-six-year-old.
Centanafadine Could Become the First Non-Stimulant Triple Reuptake Inhibitor for ADHD
While ARYNTA builds on a familiar molecule, centanafadine represents something genuinely new. Developed by Otsuka Pharmaceutical, centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor — what researchers call an NDSRI. The FDA accepted the new drug application on January 27, 2026, and granted it priority review status, setting a target action date of July 24, 2026. If approved, it would be the first non-stimulant medication that acts on all three of these neurotransmitter systems simultaneously, a mechanism that distinguishes it from existing non-stimulants like atomoxetine (Strattera), which targets norepinephrine alone, and guanfacine (Intuniv), which works through alpha-2 adrenergic receptors. The clinical evidence behind centanafadine comes from four pivotal Phase 3 trials that demonstrated statistically significant improvements on the ADHD Rating Scale-5 compared to placebo.
One of those trials enrolled 480 children between the ages of six and twelve, and the high-dose arm produced significant symptom improvement. The most common side effects reported in children and adolescents included decreased appetite, nausea, rash, fatigue, abdominal pain, and somnolence — a side effect profile that overlaps with stimulant medications in some respects but carries no scheduled substance classification, which may matter for families who are uncomfortable with or unable to use controlled substances. For caregivers weighing their options, centanafadine’s appeal lies in the possibility of a non-stimulant that addresses a broader range of neurotransmitter activity than current alternatives. That said, priority review does not guarantee approval. The FDA could request additional data, issue a complete response letter, or approve the drug with specific restrictions. Until the July 2026 decision date passes, centanafadine remains a promising candidate, not a confirmed option.
How CTx-1301 Compares to Existing Extended-Release Stimulants
CTx-1301, developed by Cingulate Inc., is a novel extended-release formulation of dexmethylphenidate — the same active ingredient found in Focalin XR. The FDA accepted the new drug application via the 505(b)(2) pathway, which allows Cingulate to reference existing clinical data on dexmethylphenidate while submitting its own evidence for the new formulation. The PDUFA target action date is May 31, 2026, meaning a decision could come before centanafadine’s. What differentiates CTx-1301 from existing extended-release methylphenidate products is its claimed pharmacokinetic profile. Phase 3 trial results showed statistically significant improvements in ADHD symptoms across the 18.75 mg, 25 mg, and 37.5 mg doses, with effect sizes ranging from 0.737 to 1.185 within five weeks.
Those are strong effect sizes by clinical standards. More notably, the drug demonstrated rapid onset of effect combined with sustained efficacy through the evening hours, addressing one of the most common complaints about existing extended-release stimulants: that they wear off too early, leaving children unmedicated during homework time, dinner, and evening routines. For a family whose child currently takes a morning dose of Focalin XR and then needs a short-acting booster in the afternoon, a single-dose option that covers the entire active day would simplify both the treatment regimen and the child’s experience of it. The tradeoff, as with any stimulant, is the side effect profile inherent to the drug class — appetite suppression, potential sleep disruption, cardiovascular effects that require monitoring, and the regulatory burden of a Schedule II substance. Families comparing CTx-1301 to centanafadine are essentially weighing the historically stronger symptom control of stimulants against the potentially more favorable risk profile of a non-stimulant. That conversation belongs between the prescriber and the family, not in a headline.
Weight Loss Warnings and What Families Should Watch For
In 2025, the FDA added expanded labeling warnings for extended-release stimulant medications regarding weight loss risk in patients younger than six who receive these drugs off-label. This is a meaningful regulatory signal. While the standard minimum age for FDA-approved ADHD medications is six, off-label prescribing of stimulants to younger children does occur, and the agency’s decision to strengthen warnings reflects accumulated data showing that developing children in that age range may be particularly vulnerable to stimulant-related appetite suppression and growth effects. For children who are six and older — the approved population for ARYNTA, and the target population for centanafadine and CTx-1301 — weight and growth monitoring remain standard components of ongoing care. Decreased appetite is listed among the most common side effects for all three of these medications. A child who loses interest in eating may not report it, and the effects can be gradual enough that parents miss the trend without regular weigh-ins.
Pediatricians typically recommend tracking height and weight on growth charts at regular intervals, adjusting doses or switching medications if growth trajectories flatten in concerning ways. There is also a subtler issue worth naming. ADHD medications are not interchangeable, and what works for one six-year-old may be intolerable for another. Families sometimes cycle through multiple medications before finding the right fit, and each transition period carries its own disruption to the child’s routine, behavior, and sense of normalcy. The arrival of new options like ARYNTA, centanafadine, and CTx-1301 expands the menu, but it does not eliminate the trial-and-error nature of ADHD pharmacotherapy. Setting realistic expectations — with the prescriber and within the family — is as important as the prescription itself.
What This Means for Older Adults and Dementia Caregiving
ADHD does not end in childhood, and its intersection with aging and cognitive decline is an area that deserves more attention than it typically receives. Adults diagnosed with ADHD in midlife or later sometimes find that existing treatments become harder to manage as swallowing difficulties, polypharmacy, and cognitive changes complicate medication adherence. ARYNTA’s liquid formulation is directly relevant here.
An older adult with mild cognitive impairment who also has ADHD — a combination that is more common than many clinicians assume — may benefit from a precisely dosed liquid that a caregiver can administer without the friction of pill-swallowing. Similarly, caregivers themselves often manage their own ADHD while providing round-the-clock support for a family member with dementia, and treatment options that reduce daily complexity matter in that context. The development of centanafadine also has implications for older patients. Stimulant medications carry cardiovascular risks that become more significant with age, and a non-stimulant option with a broader mechanism of action could fill a genuine gap for adults who need ADHD treatment but have contraindications to stimulant use — a population that includes many older adults with hypertension, arrhythmias, or other cardiac concerns.
What to Expect Through the Rest of 2026
The next several months will be decisive. CTx-1301 faces its FDA decision by May 31, 2026. Centanafadine’s target action date is July 24, 2026. ARYNTA, already approved, is expected to reach pharmacy shelves by mid-2026.
If all three move forward on schedule, the ADHD treatment landscape for children aged six and older will look meaningfully different by the end of the year — with a new liquid stimulant option, a potentially first-in-class non-stimulant, and an extended-release stimulant designed for full-day coverage all available or in the final stages of review. For families, clinicians, and caregivers, the practical advice is straightforward: stay in contact with your prescriber, ask specifically about these medications at your next appointment if they seem relevant to your situation, and resist the urge to make changes based on headlines alone. FDA approval is a necessary step, but it is not a substitute for individualized clinical judgment. The best medication for any given six-year-old — or sixty-year-old — is the one that works for that person, at that dose, with that set of tradeoffs, managed by a clinician who knows their history.
Conclusion
The FDA’s approval of ARYNTA marks a concrete step forward for ADHD treatment in young children and others who cannot easily swallow pills, delivering a familiar and well-studied medication in a form that addresses a real, everyday barrier to adherence. Alongside ARYNTA, the pending reviews of centanafadine and CTx-1301 suggest that 2026 may bring the most significant expansion of ADHD pharmacotherapy options in years — including the possibility of the first non-stimulant triple reuptake inhibitor and an extended-release stimulant with true full-day coverage.
None of these developments eliminate the complexity of treating ADHD, particularly in children. Medication is one part of a broader management strategy that includes behavioral interventions, school accommodations, family support, and ongoing monitoring. What these new and pending approvals do offer is more choices and fewer compromises — which, for a parent trying to help a six-year-old hold it together through a school day, or a caregiver managing their own focus while supporting a loved one with dementia, is no small thing.
Frequently Asked Questions
What age can children start taking ARYNTA?
ARYNTA is FDA-approved for ADHD treatment in patients aged six years and older. The FDA generally uses age six as the standard minimum for approved ADHD medications, and in 2025 added expanded weight loss warnings specifically for extended-release stimulants used off-label in children younger than six.
Is ARYNTA available at pharmacies now?
Not yet. Although the FDA approved ARYNTA on June 16, 2025, Azurity Pharmaceuticals has stated that the oral solution is expected to become available at pharmacies by mid-2026.
How is centanafadine different from existing non-stimulant ADHD medications?
Centanafadine would be the first non-stimulant that inhibits the reuptake of norepinephrine, dopamine, and serotonin simultaneously. Existing non-stimulants like atomoxetine target only norepinephrine, while guanfacine works through a different mechanism entirely. This triple reuptake approach may offer broader symptom coverage, though the FDA has not yet approved the drug.
What are the most common side effects of these new ADHD medications in children?
For centanafadine, the most common side effects reported in children and adolescents during clinical trials were decreased appetite, nausea, rash, fatigue, abdominal pain, and somnolence. ARYNTA, as a lisdexamfetamine product, carries the well-established side effect profile of that drug class, including appetite suppression, insomnia, and potential growth effects that require monitoring.
Can older adults with ADHD and swallowing difficulties use ARYNTA?
Yes. ARYNTA’s liquid formulation was designed specifically for patients who have difficulty swallowing capsules or tablets, which includes elderly patients with dysphagia, stroke survivors, and individuals with neurodegenerative conditions. However, prescribers should evaluate cardiovascular risk and potential drug interactions before starting any stimulant in an older adult.
When will the FDA decide on centanafadine and CTx-1301?
The FDA’s target action date for CTx-1301 is May 31, 2026, and for centanafadine it is July 24, 2026. These dates represent the agency’s deadline to issue a decision but do not guarantee approval.
